ACTH(4-10) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
1995: British geomorphologist Marjorie Sweeting published the first comprehensive Western account of China's karst, entitled Karst in China: its Geomorphology and Environment. 1995: Israeli-Canadian mathematical biologist Leah Keshet became the first female president of the international Society for Mathematical Biology. 1995: British geochemist Jane Plant became the first female deputy director of the British Geological Survey. 1995: Inspectors from the United Nations Special Commission discovered that Iraqi microbiologist Rihab Taha, nicknamed "Dr. Germ", had been overseeing a secret 10-year biological warfare development program in Iraq. 1996: American planetary scientist Margaret G. Kivelson led a team that discovered the first subsurface, saltwater ocean on an alien world, on the Jovian moon Europa. 1997: Lithuanian-Canadian primatologist Birutė Galdikas received the Tyler Prize for Environmental Achievement for her research and rehabilitation work with orangutans. Her work with orangutans, eventually spanning over 30 years, was later recognized in 2014 as one of the longest continuous scientific studies of wild animals in history. 1997: Chilean astronomer María Teresa Ruiz discovered Kelu 1, one of the first observed brown dwarfs. In recognition of her discovery, she became the first woman to receive the Chilean National Prize for Exact Sciences. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. Late 1990s: Ethiopian-American chemist Sossina M. Haile developed the first solid acid fuel cell.
15 January – Denis Connaghan, 79, footballer (Celtic, St Mirren, Morton). (death announced on this date) 27 January – Stuart Gray, 50, footballer (Celtic, Reading, Rushden & Diamonds), cancer. (death announced on this date) 30 January – Ally Shewan, 83, footballer (Aberdeen) and manager (Elgin City). (death announced on this date) 4 February – Mallorca Lee, 51, DJ, producer, (Ultra-Sonic), (Public Domain). 9 February – Peter Handyside, 49, footballer (Grimsby Town, Stoke City, Barnsley). 16 February – Ian McMillan, 92, footballer (Airdrieonians, Rangers, national team). (death announced on this date) 23 February – Harry Melrose, 88, footballer (Dunfermline Athletic, Aberdeen, Berwick Rangers) and manager. (death announced on this date) 24 February – Stewart Robertson, 75, conductor. (death announced on this date) 29 February – Tiffany Scott, 32, sex offender and transgender prisoner. 7 March – Nick Sheridan, 32, Irish journalist and television presenter (News2day, Reporting Scotland, The Nine) (Death announced on this date) 14 March – Angela McCluskey, 64, Scottish singer (Wild Colonials) and songwriter ("Breathe"). 15 March – Peter Kelly, 82, Scottish actor (The Tall Guy, Welcome to Sarajevo). 18 March – Peter McAleese, 81, Scottish soldier and mercenary. 20 March – Billy Kellock, 70, Scottish footballer (Cardiff City, Peterborough United, Wolverhampton Wanderers). 29 March – Iain McChesney, 79, Scottish footballer (Queen of the South). 14 April – Vincent Friell, 64, Scottish actor (Trainspotting, Restless Natives, The Angels' Share).
A ligament is a small band of dense, white, fibrous elastic tissue. Ligaments connect the ends of bones together in order to form a joint. Most ligaments limit dislocation, or prevent certain movements that may cause breaks. Since they are only elastic they increasingly lengthen when under pressure. When this occurs the ligament may be susceptible to break resulting in an unstable joint. Ligaments may also restrict some actions: movements such as hyper extension and hyper flexion are restricted by ligaments to an extent. Also ligaments prevent certain directional movement.
Microfluidic devices with 2D or 3D cell cultures can be used to analyze spheroids for different cancer systems (such as lung cancer and ovarian cancer), and are essential for multiple anti-cancer drugs and toxicity tests. This strategy can be improved by increasing the throughput and production of spheroids. For example, one droplet-based microfluidic device for 3D cell culture produces 500 spheroids per chip. These spheroids can be cultured longer in different surroundings to analyze and monitor. The other advanced technology is organs‐on‐a‐chip, and it can be used to simulate several organs to determine the drug metabolism and activity based on vessels mimicking, as well as mimic pH, oxygen... to analyze the relationship between drugs and human organ surroundings. One strategy relevant to single-cell chromatin immunoprecipitation (ChiP)‐Sequencing is droplets, which operates by combining droplet‐based single cell RNA sequencing with DNA‐barcoded antibodies, possibly to explore the tumor heterogeneity by the genotype and phenotype to select the personalized anti-cancer drugs and prevent the cancer relapse.
== Function == LepA is suspected to improve the fidelity of translation by recognizing a ribosome with mistranslocated tRNA and consequently inducing a back-translocation. By back-translocating the already post-transcriptionally modified ribosome, the EF-G factor capable of secondary translocation. Back-translocation by LepA occurs at a similar rate as an EF-G-dependent translocation. As mentioned above, EF-G's structure is highly analogous to LepA's structure; LepA's function is thus similarly analogous to EF-G's function. However, Domain IV of EF-G has been shown through several studies to occupy the decoding sequence of the A site after the tRNAs have been translocated from A and P sites to the P and E sites. Thus, domain IV of EF-G prevents back-movement of the tRNA. Despite the structural similarities between LepA and EF-G, LepA lacks this Domain IV. Thus LepA reduces the activation barrier between Pre and POST states in a similar way to EF-G but is, at the same time, able to catalyze a back-translocation rather that a canonical translocation.
Sources: en.wikipedia.org
These compounds are often not detected by routine toxicology tests and can be masked by the presence of a known compound in the same sample. As new compounds are discovered, known spectra are determined and entered into the databases that can be downloaded and used as reference standards. Laboratories also tend to keep in-house databases for the substances they find locally.
In the Druze Faith, Jesus is considered and revered as one of the seven spokesmen or prophets (natiq), defined as messengers or intermediaries between God and mankind, along with Adam, Noah, Abraham, Moses, Muhammad and Muhammad ibn Isma'il, each of them sent in a different period of history to preach the message of God. The Druze venerate Jesus "the son of Joseph and Mary" and his four disciples, who wrote the Gospels. According to the Druze manuscripts Jesus is the Greatest Imam and the incarnation of Ultimate Reason (ʿAql) on earth and the first cosmic principle (Ḥadd), and regards Jesus and Hamza ibn Ali as the incarnations of one of the five great celestial powers, who form part of their system. Druze doctrines include the beliefs that Jesus was born of a virgin named Mary, performed miracles, and died by crucifixion. Druze doctrines include that Hamza ibn Ali took Jesus down from the cross and allowed him to return to his family, to prepare men for the preaching of his religion. In the Druze tradition, Jesus is known under three titles: the True Messiah (al-Masiḥ al-Haqq), the Messiah of all Nations (Masiḥ al-Umam), and the Messiah of Sinners. This is due, respectively, to the belief that Jesus delivered the true Gospel message, the belief that he was the Saviour of all nations, and the belief that he offers forgiveness. The Druze shrine of "Sayyidna al-Masih" (Our Lord Jesus), one of the most important religious sites for the Druze, is located on a high mountain peak in the Al-Bajjah area of As-Suwayda Governorate.
The studies are progressively longer, gradually adding more individuals as they progress from stage I to stage III, normally over a period of years, and normally involve drug companies, the government and its laboratories, and often medical schools and hospitals and clinics. However, any exceptions to the aforementioned process are subject to strict review and scrutiny and conditions, and are only given if a substantial amount of research and at least some preliminary human testing has shown that they are believed to be somewhat safe and possibly effective. (See FDA Special Protocol Assessment about Phase III trials.)
Unlike traditional techniques such as embryo gene editing, which directly alter the genome of an existing embryo and are therefore person-affecting, these synthetic gametes are built de novo and give rise to individuals who would not have existed otherwise, making the intervention non-person-affecting in the sense of Parfit. Gametes produced in this way, which are distinct from artificial gametes obtained through in vitro–derived gametogenesis, raise ethical questions regarding reproductive autonomy, identity, and the design of human traits without impacting pre-existing persons.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.